2J1W

Human p53 core domain mutant M133L-V143A-V203A-N239Y-N268D

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.8 Å
  • R-Value Free: 0.206 
  • R-Value Work: 0.185 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history. 

Literature

Structural Basis for Understanding Oncogenic P53 Mutations and Designing Rescue Drugs.

Joerger, A.C., Ang, H.C., Fersht, A.R.

(2006) Proc.Natl.Acad.Sci.USA 103: 15056

  • DOI: 10.1073/pnas.0607286103
  • Primary Citation of Related Structures:  
  • Also Cited By: 6GGF, 6GGE, 6GGD, 6GGC, 6GGB, 6GGA, 4AGQ, 4AGP, 4AGO, 4AGN, 4AGM, 4AGL, 3ZME, 2X0W, 2X0V, 2X0U, 2VUK

  • PubMed Abstract: 

    • The DNA-binding domain of the tumor suppressor p53 is inactivated by mutation in approximately 50% of human cancers. We have solved high-resolution crystal structures of several oncogenic mutants to investigate the structural basis of inactivation an ...

    The DNA-binding domain of the tumor suppressor p53 is inactivated by mutation in approximately 50% of human cancers. We have solved high-resolution crystal structures of several oncogenic mutants to investigate the structural basis of inactivation and provide information for designing drugs that may rescue inactivated mutants. We found a variety of structural consequences upon mutation: (i) the removal of an essential contact with DNA, (ii) creation of large, water-accessible crevices or hydrophobic internal cavities with no other structural changes but with a large loss of thermodynamic stability, (iii) distortion of the DNA-binding surface, and (iv) alterations to surfaces not directly involved in DNA binding but involved in domain-domain interactions on binding as a tetramer. These findings explain differences in functional properties and associated phenotypes (e.g., temperature sensitivity). Some mutants have the potential of being rescued by a generic stabilizing drug. In addition, a mutation-induced crevice is a potential target site for a mutant-selective stabilizing drug.

    Related Citations: 
    • Crystal Structure of a Superstable Mutant of Human P53 Core Domain. Insights Into the Mechanism of Rescuing Oncogenic Mutations.
      Joerger, A.C.,Allen, M.D.,Fersht, A.R.
      (2004) J.Biol.Chem. 279: 1291
    • Structures of P53 Cancer Mutants and Mechanism of Rescue by Second-Site Suppressor Mutations.
      Joerger, A.C.,Ang, H.C.,Veprintsev, D.B.,Blair, C.M.,Fersht, A.R.
      (2005) J.Biol.Chem. 280: 16030

    Organizational Affiliation: 

    Cambridge University Chemical Laboratory and Cambridge Centre for Protein Engineering, Medical Research Council Centre, Hills Road, Cambridge CB2 2QH, United Kingdom.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
CELLULAR TUMOR ANTIGEN P53
A, B
219Homo sapiensMutation(s): 5 
Gene Names: TP53 (P53)
Find proteins for P04637 (Homo sapiens)
Go to Gene View: TP53
Go to UniProtKB:  P04637
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
ZN
Query on ZN
Download SDF File 
Download CCD File 
A, B
ZINC ION
Zn
PTFCDOFLOPIGGS-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.8 Å
  • R-Value Free: 0.206 
  • R-Value Work: 0.185 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 64.656α = 90.00
b = 71.066β = 90.00
c = 105.001γ = 90.00
Software Package:
Software NamePurpose
CNSphasing
CNSrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots


View more in-depth experimental data

Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2006-09-20
    Type: Initial release
  • Version 1.1: 2011-05-08
    Type: Version format compliance
  • Version 1.2: 2011-07-13
    Type: Version format compliance